Skip to content

Flow augmentation study

Flow augmentation study - Geko study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON55885
Enrollment
51
Registered
2017-02-15
Start date
2017-04-03
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

blod flow post trombotic syndrome

Interventions

Geko device versus IPCS or open fistula

Sponsors

Vaatchirurgie
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Only patients that fulfill either a) or b) and c) are able to participate into this study: a) Patients that suffer from post-thrombotic obstruction, which are in need of a percutaneous intervention by stenting (will be considered as study percutaneous group 1). b) Patients that suffer from post-thrombotic obstruction whereby endophlebectomy and placement of an AVF has to be performed (will be considered as study hybrid group 2). c) Patients have to be minimally 18 years of age or older.

Exclusion criteria

Exclusion criteria: Peripheral arterial disease, comorbidities leading to impaired muscle function of either lower limb, co-morbidities affecting the circulatory system, history of deep venous surgery in either lower limb or groin, allergies to the plasters, pregnancy.

Design outcomes

Primary

MeasureTime frame
The main endpoint and parameter of this study is time-averaged maximum flow velocity (TAMFV), measured by duplex ultrasonography (DUS) using its pulse wave Doppler function

Secondary

MeasureTime frame
Sex, age and body mass index will be obtained for demographic purposes. VAS score will be collected to evaluate the tolerability of the devices. Villalta score, Venous Clinical Severity Score, extent of post-thrombotic disease based on DUS and magnetic resonance venography, history of previous venous interventions, and CEAP score, will also be collected.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)